1 / 16

GAP - Overall Goal

GAP - Overall Goal. F acilitates and administers MD Anderson's Sister Institution Network (the largest network of cancer centers) working collaboratively on education, research, patient care aimeing at lessening the world's cancer burden.

mai
Télécharger la présentation

GAP - Overall Goal

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. GAP - Overall Goal Facilitates and administers MD Anderson's Sister Institution Network (the largest network of cancer centers) working collaboratively on education, research, patient care aimeingat lessening the world's cancer burden

  2. MDACC Global Academic ProgramsSister Institution Network (N= 26)

  3. SINF National Breast Cancer Foundation: $300,000

  4. Joint Publications

  5. Joint Publications • Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, Gou X, Aldape K, Lu Z. Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature, 480(7375):118–22, 2011. • Dietrich S, Glimm H, Andrulis M, Kalle von C, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med,366(21):2038–40, 2012. • Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, Aldape K, Hunter T, Alfred Yung WK, Lu Z. PKM2 Phosphorylates Histone H3 and Promotes Gene Transcription and Tumorigenesis. Cell, 150(4):685–96, 2012. • Zhang M, Maiti S, Bernatchez C, Huls H, Rabinovich B, Champlin RE, Vence LM, Hwu P, Radvanyi L, Cooper LJ. A New Approach to Simultaneously Quantify Both TCR - and -Chain Diversity after Adoptive Immunotherapy. Clin Cancer Res, 18(17):4733–42, 2012.

  6. Nasopharyngeal Carcinoma RTOG CUHK CGU, NTU MDACC

  7. Nasopharyngeal Carcinoma 5-Year Disease Specific Survival Rate ~80% ~50% ~35% 0% 1930 2000 1985 1969 Source: Anne Lee, Pamela YoudeNethersole Eastern Hospital, Hong Kong

  8. NPC: Stage at Diagnosis Anne Lee (PYNEH-Hong Kong) 1994-2005: 1185 patients

  9. Nasopharyngeal Carcinoma 5-Year Disease Specific Survival Rate Chemotherapy & IMRT ~80% LINAC ~50% Cobalt ~35% 0% 1930 2000 1985 1969 Source: Anne Lee, Pamela YoudeNethersole Eastern Hospital, Hong Kong

  10. 100 90 80 70 60 50 40 30 20 10 0 0 10 20 30 40 50 60 70 Standard Therapy for Locally Advanced NPCIMRT+ CDDP  CDDP+FU x3 5-Y nodal control: 97% 5-Y primary tumor control: 94% 5-Y metastasis-free: 66% N= 87 Median FU=30 months Percent P= 0.005 Intergroup Trial Al-Sarrafet al., JCO, 1998 Validation: Wee et al., JCO, 2005 Months Lee et al., IJROBP, 2002

  11. IMRT + Chemotherapy for NPC

  12. Nasopharyngeal Carcinoma Impact of Post-Rx EBV Titer on Outcome <500 copies <500 copies >500 copies >500 copies Chan et al., JNCI 94: 1614, 2002 (Chinese University of Hong Kong) Validation: Lin et al., NEJM, 2004 (Taiwan); Le et al., CCR, 2004 (US)

  13. NPC Trial Concept Observe REGISTER T≥2 or N+ WHO I-III Phase III: 770 EBV= 0 IMRT (70 Gy) + CDDP (40 mg/m2 X7) CDDP + 5FU x3 EBV>0 Phase IIR: 156 R R Taxane + Gem IMRT Credentialing & QA EBV Assay Harmonization

  14. Primary PTV Secondary PTV Organ at Risk Credentialing & QA: IMRT H&N Phantom • Primary PTV 4 cm diameter 4 TLD • Secondary PTV 2 cm diameter 2 TLD • Organ at risk 1 cm diameter 2 TLD • Axial and sagittal radiochromic films 1º PTV treated to 6.6 Gy 2º PTV treated to 5.4 Gy OAR limited to < 4.5 Gy Designed in collaboration with RTOG; Molineu et al, IJROBP, October 2005 MDACC (P01 funded)

  15. Results of Two Centers

  16. EBV Assay An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus (EBV) DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma Le QT1, Zhang Q2,Cao HB1, Cheng AJ3, Pinsky BA1, Hong RL4, Chang JT3, Wang CW4, Kuo-ChienTsao KC3, Lo YMD6, Lee N5, Ang KK7, Chan ATC6, Chan AKC6 1Stanford University, 2RTOG Statistical Center, 3Chang-Gung University,4National Taiwan University Hospital, 5Memorial Sloan Kettering Cancer Center,6The Chinese University of Hong Kong, 7M.D. Anderson Cancer Center

More Related